The use of Ambroxol for the treatment of Gaucher disease: A systematic review
eJHaem · 2024-02 · 5 (1) · 206-221
DOI: 10.1002/jha2.852 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift eJHaem, online erschienen am 30.01.2024. Verfasst von Diego Agustín Abelleyra Lastoria und 2 weiteren Autor:innen. Beteiligte Einrichtung: Institute for Medical and Biomedical Education St. George's, University of London London UK. Die Arbeit wurde bisher 13-mal zitiert (Crossref) und nennt 43 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Gaucher disease (GD) is a heterogeneous condition requiring tailored treatment approaches. The aim of this systematic review was to synthesise and evaluate current evidence pertaining to the use of Ambroxol for the treatment of GD. Published and unpublished literature databases, conference proceedings and the reference lists of included studies were searched until 23 November 2023. A narrative synthesis was performed. Database search and risk of bias assessment were performed independently by two reviewers. Twenty‐one studies (182 patients) were included. The evidence was low in quality. Variable responses to Ambroxol were observed. Response rates were 36% and 55% in two studies reporting on type 1 GD. One study found a 22% response rate in type 2 GD, whereas another study found 29% of patients with type 3 GD reported neurological improvements. No severe adverse events were reported in the literature, with mild and reversible side effects reported. Varying response rates are to be expected (29%–100%) when treating neurological manifestations. Varying degrees of symptomatic improvement for the treatment of GD were noted in the literature. Multidisciplinary team input and clinical judgement are advised to provide personalized treatment of this complex and multi‐faceted condition.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Institute for Medical and Biomedical Education St. George's, University of London London UK.
- Lysosomal Storage Disorders Unit Royal Free London NHS Foundation Trust University College London London UK.
ORCID-Profile: Diego Agustín Abelleyra Lastoria
Zitieren
APA
Abelleyra Lastoria, D. A., Grewal, S., & Hughes, D. (2024). The use of Ambroxol for the treatment of Gaucher disease: A systematic review. eJHaem, 5(1), 206-221. https://doi.org/10.1002/jha2.852
Vancouver
Abelleyra Lastoria DA, Grewal S, Hughes D. The use of Ambroxol for the treatment of Gaucher disease: A systematic review. eJHaem. 2024;5(1):206-221. doi:10.1002/jha2.852
BibTeX
@article{AbelleyraLastoria2024,
author = {Abelleyra Lastoria, Diego Agustín and Grewal, Simranjeet and Hughes, Derralynn},
title = {The use of Ambroxol for the treatment of Gaucher disease: A systematic review},
journal = {eJHaem},
year = {2024},
volume = {5},
number = {1},
pages = {206--221},
doi = {10.1002/jha2.852}
}
EUVIMED